Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced the release of an abstract by ESMO with preliminary results from the company’s Phase 1 study of zanidatamab zovodotin, an investigational no
Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above. Data and information beyond what is included in all accepted abstracts, for example full data sets, may only be made public at the start of the official progr...
Ascentage Pharma announced that it is going to release results from two clinical studies at the 2023 European Society of Medical Oncology Congress. SUZHOU, China, and ROCKVILLE, Md., Aug. 2, 2023 /PRNewswire/ --Ascentage Pharma(6855.HK), ...
2023年10月24日,复宏汉霖(2696.HK)宣布,基于与宜联生物的合作,公司开发的靶向EGFR的抗体偶联药物(ADC)HLX42的临床前研究数据在2023 ESMO年会上以壁报形式展示。这也是复宏汉霖在ADC治疗领域最新研究成果的首次公开亮相。 尽管多款...
[6] Joel Neal et al. CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. 2023 ELCC Abstract 6O. ...
在日前结束的2023年欧洲肿瘤内科学(ESMO)年会中,TROP2 ADC首个肺癌III期研究TROPION-Lung01数据正式揭晓,奠定了Dato-DXd作为TROP2 ADC赛道领跑者地位。值此之际,医脉通特邀北京大学肿瘤医院方健教授解读TROPION-Lung01研究数据,剖析...
[2] ]Jiaqiang C, Shuai S, Qing Z, et al; Abstract 596: Development and assessment of a novel tumor microenvironment activable linker (TMALIN) ADC platform for solid tumor treatments. Cancer Res 1 April 2023; 83 (7_Supplement): 596. ...
Abstract # & Link: 289MO Session & Location: ESMO Asia – Gynaecological cancers (ID 28), Hall 401 Date & Time: Friday, December 1, 2023, 11:25 am Singapore time Title: Fruquintinib plus sintilimab in patients with advanced non-small cell lung cancer (“NSCLC”) with...
Only abstracts for whichno conclusive data are available at the time of the abstract submission deadline of9 January 2024will be considered for late-breaking status. The workmust nothave been previously published in any publication in a peer review setting or presented at a meeting of any other...
Both research results will be the first of such release by a Chinese company for the respective target. Abstract number: 1012P Title: First-in-human study of ABSK011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (...